Hypersensitivity Types I-IV

SECTION 1

Historical Context & Motivation

The concept of hypersensitivity arose from a seemingly paradoxical observation: the immune system, evolved to protect the body from pathogens and foreign substances, could itself become a source of tissue injury and disease. Throughout the late nineteenth and early twentieth centuries, clinicians and researchers documented cases in which immune responses caused harm disproportionate to any infectious threat, ranging from fatal reactions to horse serum injections to the chronic inflammation seen in autoimmune diseases. These observations challenged the prevailing view that immunity was an exclusively beneficial phenomenon and opened an entirely new field of immunopathology.

The formal classification of hypersensitivity reactions into distinct types provided clinicians with a rational framework for understanding why different immune-mediated diseases presented so differently. A patient experiencing acute anaphylaxis after a bee sting, for instance, manifests a fundamentally different immunological mechanism than a patient whose kidneys are damaged by circulating immune complexes in systemic lupus erythematosus. By categorizing these reactions, researchers could develop targeted diagnostic and therapeutic strategies, transforming the management of allergic, autoimmune, and inflammatory conditions.

1902

Discovery of Anaphylaxis

Charles Richet and Paul Portier demonstrated that dogs re-exposed to sea anemone toxin developed fatal systemic reactions rather than protection. Richet coined the term anaphylaxis (opposite of prophylaxis), earning the 1913 Nobel Prize for this work.

1905

Serum Sickness Described

Clemens von Pirquet and Béla Schick published their landmark monograph on serum sickness, describing the delayed febrile reactions, rash, and arthralgia that followed therapeutic injection of horse serum antitoxins—an early example of immune complex disease.

1948

Gruber and the Coombs Test

Robin Coombs and colleagues developed the antiglobulin test (Coombs test), enabling detection of antibodies bound to red blood cells and providing a diagnostic tool for Type II hypersensitivity reactions such as hemolytic disease of the newborn.

1963

Gell and Coombs Classification

Philip Gell and Robin Coombs published their foundational classification system dividing hypersensitivity into four types (I–IV) based on immunological mechanism. This framework remains the standard teaching model in immunology and pathophysiology to this day.

1966

Discovery of IgE

Kimishige and Teruko Ishizaka identified immunoglobulin E (IgE) as the antibody class responsible for immediate allergic reactions, completing the molecular basis for Type I hypersensitivity and opening the door to modern allergy therapeutics.

The central question that the Gell and Coombs classification addresses is deceptively simple: when the immune system causes disease rather than preventing it, what are the distinct mechanisms by which it does so? Answering this question requires understanding the interplay between antibody classes, complement activation, immune complex formation, and cell-mediated cytotoxicity—each of which defines one of the four hypersensitivity types.

SECTION 2

Core Principles & Definitions

Before examining each hypersensitivity type individually, it is essential to understand several foundational principles that underpin the entire classification system. All hypersensitivity reactions share the requirement of prior sensitization—an initial exposure to an antigen that primes the immune system, producing memory cells or antibodies capable of mounting an exaggerated response upon subsequent encounter. The distinction among the four types rests on which arm of the adaptive immune system drives the pathology, the time course of the reaction, and the nature of the tissue damage produced.

Sensitization vs. Elicitation

The first exposure to an antigen (sensitization) is clinically silent. Symptoms only appear upon re-exposure (elicitation), when the primed immune system mounts an amplified, tissue-damaging response against the recognized antigen.

Humoral vs. Cell-Mediated

Types I, II, and III are antibody-mediated (humoral), involving IgE, IgG, or IgM. Type IV is uniquely cell-mediated, driven by T lymphocytes rather than circulating antibodies.

Temporal Classification

Reactions are classified by onset: immediate (Type I, minutes), cytotoxic (Type II, hours), immune complex (Type III, hours to days), and delayed (Type IV, 24–72 hours).

Self vs. Non-Self Antigens

Hypersensitivity can target exogenous antigens (allergens, drugs, microbial products) or endogenous self-antigens. When the target is self-tissue, the reaction is classified as an autoimmune disorder, though the underlying immunopathological mechanism still follows the Gell–Coombs framework.

Effector Mechanisms

Tissue damage results from distinct effectors: mast cell degranulation (Type I), complement and phagocytes (Type II), neutrophil-driven inflammation (Type III), and macrophages and cytotoxic T cells (Type IV).

✦ KEY TAKEAWAY

Think of the immune system as a home security system. In Type I, the alarm (mast cells) goes off instantly and floods the house with fire-suppression foam (histamine) at the slightest trigger—even a family pet. In Type II, the system specifically targets and destroys a piece of furniture it wrongly identifies as an intruder. In Type III, the security drones (immune complexes) malfunction and crash into the walls, damaging the house itself. In Type IV, the security team (T cells) takes 48 hours to arrive and then uses heavy equipment to root out the perceived threat, causing collateral structural damage. Each failure mode requires a different repair strategy—just as each hypersensitivity type demands a different therapeutic approach.

SECTION 3

Visual Overview of the Four Types

The following diagram provides a comparative visual overview of all four hypersensitivity types, illustrating the key immunological mediator, the mechanism of tissue injury, and the typical time course for each. Understanding these pathways side by side allows clinicians to rapidly distinguish among them when evaluating a patient presenting with immune-mediated disease.

Figure 1: Comparative overview of the four hypersensitivity types. Each column displays the primary mediator (antibody class or T cells), the effector mechanism, the key chemical or cellular mediators released, and representative clinical examples. Note the progression from immediate onset (Type I) to delayed onset (Type IV).

As the diagram illustrates, a critical differentiator among the four types is the temporal profile. Type I reactions occur within minutes because preformed IgE is already bound to mast cells, requiring only antigen crosslinking to trigger degranulation. Types II and III require hours because antibody binding, complement activation, and cellular recruitment take time to develop. Type IV reactions are delayed by 24 to 72 hours because they depend on the migration and activation of antigen-specific T lymphocytes, which must traffic to the site of antigen exposure and orchestrate a macrophage-dominated inflammatory response. This temporal framework is a powerful diagnostic tool: a clinician who observes a reaction within minutes of allergen exposure can immediately focus on Type I mechanisms, whereas a reaction that appears two days after exposure points strongly toward Type IV.

SECTION 4

Mechanisms in Depth

Type I: Immediate (Anaphylactic) Hypersensitivity

Type I hypersensitivity is initiated when a genetically predisposed individual produces IgE antibodies against otherwise harmless environmental antigens (allergens) such as pollen, dust mite proteins, or certain food proteins. During the sensitization phase, antigen-presenting cells process the allergen and present peptides to T_H2 helper cells, which release interleukin-4 (IL-4) and interleukin-13 (IL-13), driving B-cell class switching to IgE production. The secreted IgE binds with high affinity to FcεRI receptors on the surface of mast cells and basophils, leaving the individual sensitized but asymptomatic.

Upon re-exposure, the multivalent allergen crosslinks adjacent surface-bound IgE molecules, triggering a signaling cascade that results in immediate mast cell degranulation. Preformed mediators including histamine, tryptase, and heparin are released within seconds to minutes, producing vasodilation, increased vascular permeability, smooth muscle contraction, and mucus secretion. A late-phase response follows 4–8 hours later, mediated by newly synthesized prostaglandins, leukotrienes (particularly LTC₄, LTD₄, LTE₄), and cytokines that recruit eosinophils and perpetuate inflammation.

Type II: Antibody-Mediated (Cytotoxic) Hypersensitivity

In Type II reactions, IgG or IgM antibodies bind to antigens that are intrinsic components of cell surfaces or the extracellular matrix. The bound antibodies then activate three principal effector pathways. First, they activate the classical complement pathway, generating the membrane attack complex (MAC, C5b–C9) that directly lyses target cells, as well as complement fragments C3a and C5a that recruit inflammatory cells. Second, the Fc regions of bound antibodies serve as opsonins, facilitating phagocytosis by macrophages and neutrophils. Third, antibody-coated cells can be destroyed via antibody-dependent cell-mediated cytotoxicity (ADCC), in which natural killer (NK) cells recognize the Fc portion and release cytotoxic granules.

A clinically important subtype of Type II hypersensitivity involves antibodies directed against cell surface receptors, producing functional changes without cell destruction. In Graves disease, stimulatory anti-TSH receptor antibodies mimic thyroid-stimulating hormone, causing hyperthyroidism. Conversely, in myasthenia gravis, blocking antibodies against acetylcholine receptors at the neuromuscular junction impair signal transmission, producing muscle weakness.

Type III: Immune Complex–Mediated Hypersensitivity

Type III reactions occur when antigen–antibody complexes (immune complexes) form in the circulation and deposit in tissues, particularly at sites of blood filtration such as the renal glomeruli, synovial membranes, and vessel walls. Normally, immune complexes are efficiently cleared by the mononuclear phagocyte system; however, when antigen is persistent or present in excess, intermediate-sized complexes escape clearance and lodge in vascular basement membranes. Deposited complexes activate complement, generating C3a and C5a (anaphylatoxins) that recruit neutrophils. These neutrophils attempt to phagocytose the complexes but, because the complexes are fixed to tissues, the neutrophils release lysosomal enzymes and reactive oxygen species extracellularly, causing bystander tissue injury.

Type IV: Delayed-Type (Cell-Mediated) Hypersensitivity

Type IV is the only hypersensitivity reaction that is entirely T-cell mediated and cannot be transferred by serum (antibodies). Two principal T-cell subsets drive different manifestations. CD4⁺ T_H1 cells recognize antigen presented by macrophages via MHC class II molecules and release interferon-γ (IFN-γ) and tumor necrosis factor (TNF), which activate macrophages to become highly microbicidal. Chronic macrophage activation can lead to granuloma formation, as seen in tuberculosis and sarcoidosis. CD8⁺ cytotoxic T lymphocytes (CTLs) recognize intracellular antigens presented via MHC class I and directly kill target cells via perforin–granzyme pathways, as occurs in transplant rejection and the destruction of pancreatic β-cells in type 1 diabetes mellitus.

SECTION 5

Detailed Classification & Comparison

The following comprehensive table summarizes the distinguishing features of each hypersensitivity type across multiple dimensions including immunological mediators, effector mechanisms, time course, key histological findings, and prototypical clinical conditions. This comparative framework is essential for differential diagnosis, as many diseases involve overlapping immune mechanisms.

Table 1: Comprehensive comparison of hypersensitivity Types I–IV

Feature	Type I	Type II	Type III	Type IV
Alternative Name	Immediate / Anaphylactic	Cytotoxic / Antibody-mediated	Immune complex	Delayed-type / Cell-mediated
Antibody Involved	IgE	IgG, IgM	IgG, IgM	None (T cells)
Antigen Location	Soluble (exogenous allergen)	Cell surface or ECM	Soluble (in circulation)	Cell-associated or soluble (processed by APCs)
Effector Mechanism	Mast cell/basophil degranulation	Complement (MAC), ADCC, opsonization	Complement activation, neutrophil recruitment	Macrophage activation, CTL killing
Onset	Seconds to minutes	Hours	3–10 hours (Arthus); 7–14 days (serum sickness)	24–72 hours
Key Mediators	Histamine, leukotrienes, prostaglandins, IL-4, IL-5	Complement fragments, perforins, phagocytic enzymes	C3a, C5a, neutrophil lysosomal enzymes, ROS	IFN-γ, TNF, IL-2, perforin, granzymes
Histology	Edema, smooth muscle contraction, eosinophils (late phase)	Cell lysis, linear immunofluorescence	Fibrinoid necrosis, granular ("lumpy-bumpy") IF	Mononuclear infiltrate, granulomas
Diagnostic Test	Skin prick test, serum IgE, tryptase	Direct/indirect Coombs test	Serum complement levels (↓C3, ↓C4), biopsy with IF	PPD/Mantoux test, patch test
Clinical Examples	Anaphylaxis, allergic asthma, hay fever, food allergies	AIHA, Goodpasture, Graves, myasthenia gravis, Rh disease	SLE, post-streptococcal GN, serum sickness, polyarteritis nodosa	Contact dermatitis, TB, transplant rejection, T1DM, MS

Figure 2: Clinical differentiation flowchart guiding the classification of a hypersensitivity reaction based on temporal onset, location of antigen, immunofluorescence pattern, and key diagnostic findings. Starting from patient presentation, follow the branching decision tree to arrive at the most likely hypersensitivity type.

SECTION 6

Worked Clinical Example

Clinical reasoning in hypersensitivity requires integrating the patient's history, timing of symptoms, laboratory findings, and biopsy results to identify the correct type and guide management. The following worked example demonstrates this step-by-step diagnostic process.

Case: A 28-Year-Old Woman with Hematuria and Hemoptysis

Step 1 — Gather Clinical PresentationA 28-year-old woman presents with two weeks of progressive fatigue, cola-colored urine (hematuria), and occasional blood-streaked sputum (hemoptysis). Physical exam reveals bilateral pulmonary crackles and peripheral edema. Serum creatinine is elevated at 3.2 mg/dL (normal: 0.6–1.2 mg/dL), and urinalysis shows red blood cell casts, proteinuria, and dysmorphic RBCs—features of glomerulonephritis.

Step 2 — Determine Timing and OnsetThe disease evolved over days to weeks, not minutes (ruling out Type I) and not in a single acute episode lasting 24–72 hours (less consistent with isolated Type IV). The subacute onset with progressive organ damage over days to weeks is consistent with either Type II or Type III hypersensitivity. Both can produce glomerulonephritis, so further workup is needed.

Step 3 — Order Targeted DiagnosticsSerological testing reveals anti-glomerular basement membrane (anti-GBM) antibodies (positive). Complement levels (C3, C4) are normal, which argues against immune complex disease (Type III typically consumes complement). A renal biopsy is performed.

Anti-GBM positive; complement normal → favors Type II

Step 4 — Analyze Biopsy and ImmunofluorescenceRenal biopsy demonstrates crescentic glomerulonephritis with fibrinoid necrosis. Immunofluorescence microscopy reveals a characteristic smooth, linear pattern of IgG deposition along the glomerular basement membrane. This linear pattern is the pathognomonic hallmark of Type II hypersensitivity affecting the kidney, distinguishing it from the granular ("lumpy-bumpy") pattern seen in Type III immune complex deposition.

Linear IgG on IF → confirmed Type II mechanism

Step 5 — Establish Diagnosis and MechanismThe combination of anti-GBM antibodies, linear IF staining, pulmonary hemorrhage, and rapidly progressive glomerulonephritis establishes the diagnosis of Goodpasture syndrome (anti-GBM disease). This is a Type II hypersensitivity reaction in which IgG autoantibodies target the α3 chain of type IV collagen in the basement membranes of the lungs and kidneys. The antibodies activate complement locally, recruiting neutrophils and macrophages that cause direct tissue destruction. Treatment involves plasmapheresis (to remove circulating anti-GBM antibodies), corticosteroids, and cyclophosphamide (to suppress further antibody production).

Diagnosis: Goodpasture syndrome — Type II hypersensitivity against basement membrane collagen

SECTION 7

Clinical Correlations & Therapeutic Strategies

Understanding the mechanistic basis of each hypersensitivity type has direct therapeutic implications. Because each type operates through a distinct immunological pathway, treatment strategies differ fundamentally—from blocking mediator release in Type I to depleting pathogenic antibodies in Type II and immunosuppressing T cells in Type IV. The following table summarizes the principal therapeutic approaches for each type, highlighting both established treatments and emerging targeted therapies.

Table 2: Therapeutic strategies organized by hypersensitivity type

Therapeutic Strategy	Type I	Type II	Type III	Type IV
Avoidance / Prevention	Allergen avoidance, desensitization (immunotherapy)	Blood type matching, drug avoidance	Minimize antigen exposure (e.g., avoid causative drugs)	Avoid contactants (e.g., nickel, poison ivy)
Acute Management	Epinephrine (IM), antihistamines (H₁/H₂), corticosteroids, bronchodilators	Transfusion support, IV immunoglobulin	NSAIDs, corticosteroids for acute inflammation	Topical/systemic corticosteroids
Immunomodulation	Omalizumab (anti-IgE monoclonal Ab), leukotriene inhibitors (montelukast)	Plasmapheresis, rituximab (anti-CD20), cyclophosphamide	Cyclophosphamide, mycophenolate, belimumab (anti-BAFF)	Calcineurin inhibitors (tacrolimus, cyclosporine), anti-TNF agents
Targeted Biologic	Dupilumab (anti-IL-4Rα), mepolizumab (anti-IL-5)	Eculizumab (anti-C5, for complement-mediated hemolysis)	Anifrolumab (anti-IFN receptor, for SLE)	Abatacept (CTLA-4-Ig, blocks T-cell co-stimulation)

✦ KEY TAKEAWAY

The therapeutic principle across all hypersensitivity types is analogous to troubleshooting a malfunctioning industrial process: you must first determine which component of the system is failing (the sensor, the actuator, the feedback loop, or the controller) before you can apply the correct fix. Administering epinephrine for a Type IV reaction or calcineurin inhibitors for anaphylaxis would be not only ineffective but potentially harmful. Accurate classification drives rational therapy—the Gell–Coombs framework is therefore not merely academic but a clinical decision-making tool.

SECTION 8

Connections to Advanced Immunopathology

While the Gell–Coombs classification provides an indispensable framework, modern immunology recognizes that many clinical diseases involve overlapping mechanisms that do not fit neatly into a single type. Systemic lupus erythematosus, for example, is predominantly a Type III immune complex disease, but patients may also exhibit Type II cytotoxic hemolytic anemia and Type IV delayed-type hypersensitivity reactions in affected tissues. Rheumatoid arthritis involves both immune complex deposition in joints (Type III) and T-cell-mediated synovial inflammation (Type IV). Understanding these overlaps is essential for advanced clinical immunology and guides the selection of combination immunosuppressive regimens.

Table 3: Classic vs. Modern understanding of hypersensitivity

Concept	Classic Gell–Coombs Framework	Modern Immunopathology
Disease Classification	Each disease assigned to one type	Many diseases involve multiple types simultaneously
Type IV Subtypes	Type IV treated as a single entity	Subdivided into IVa (Tₕ1/macrophage), IVb (Tₕ2/eosinophil), IVc (CTL), IVd (T cell/neutrophil)
Role of Innate Immunity	Focused on adaptive immune effectors	Innate immune activation (TLRs, inflammasomes, NETs) amplifies all types
Therapeutic Approach	Broad immunosuppression (corticosteroids)	Precision biologics targeting specific mediators (anti-IgE, anti-C5, anti-IL-4Rα, CTLA-4-Ig)
Immune Checkpoints	Not addressed in original framework	Checkpoint inhibitor therapy (anti-PD-1, anti-CTLA-4) can induce all four types of hypersensitivity as immune-related adverse events

An increasingly important clinical context is the emergence of immune-related adverse events (irAEs) in patients receiving checkpoint inhibitor immunotherapy for cancer. By releasing the brakes on T-cell activation, drugs such as nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) can unleash hypersensitivity reactions across all four Gell–Coombs types: Type I–like infusion reactions, Type II autoimmune cytopenias, Type III vasculitis, and Type IV granulomatous inflammation. Recognizing these reactions and classifying them correctly is essential for oncology nurses and clinicians managing these patients, as treatment requires balancing the benefits of continued immunotherapy against the risks of immune-mediated organ damage.

🔬 Looking Ahead

Advanced courses in clinical immunology will explore the molecular mechanisms of immune tolerance and how its breakdown leads to autoimmune disease, the pharmacology of biologic agents that target specific steps in each hypersensitivity pathway, and the immunopathology of transplant rejection (which involves Types II, III, and IV simultaneously). Mastery of the Gell–Coombs framework provides the conceptual scaffolding for all of these advanced topics.

SECTION 9

Practice Problems

PROBLEM 1 — CONCEPTUAL

Explain why Type IV hypersensitivity reactions cannot be transferred from one individual to another by serum transfer, whereas Types I, II, and III can. What fundamental immunological distinction accounts for this difference?

PROBLEM 2 — BASIC CALCULATION

A patient with suspected anaphylaxis has a serum tryptase level of 42 ng/mL measured 1 hour after the onset of symptoms. The baseline tryptase (drawn 24 hours later) is 5 ng/mL. Using the formula: elevated tryptase is clinically significant if the acute level exceeds (1.2 × baseline) + 2 ng/mL, determine whether this patient's tryptase result supports the diagnosis of anaphylaxis.

PROBLEM 3 — INTERMEDIATE

A 10-year-old child develops fever, urticaria, lymphadenopathy, and joint pain 10 days after receiving equine antivenom for a rattlesnake bite. Serum complement levels (C3 and C4) are depressed. What hypersensitivity type is responsible, and what is the pathophysiological mechanism producing each of the child's symptoms?

PROBLEM 4 — APPLIED

A nurse administers penicillin intravenously to a patient who reports a history of 'penicillin allergy.' Within 5 minutes, the patient develops generalized urticaria, angioedema, wheezing, and hypotension (BP 70/40 mmHg). (A) Identify the hypersensitivity type and explain the complete immunological cascade occurring in this patient. (B) Outline the immediate pharmacological management, explaining the mechanism of action of each drug in the context of the underlying pathophysiology.

PROBLEM 5 — CRITICAL THINKING

A 55-year-old man with metastatic melanoma begins treatment with nivolumab (anti-PD-1 checkpoint inhibitor). Six weeks later, he develops autoimmune hepatitis (elevated transaminases, lymphocytic portal infiltrate on biopsy) and autoimmune hemolytic anemia (positive direct Coombs test, spherocytes on smear). Analyze which Gell–Coombs hypersensitivity type(s) are operating in each of these immune-related adverse events, explain why checkpoint inhibitor therapy predisposes to multiple hypersensitivity types simultaneously, and discuss the clinical dilemma this creates for the treating oncologist.

SUMMARY

Hypersensitivity Types I–IV: Summary

The Gell–Coombs classification organizes immune-mediated tissue injury into four mechanistically distinct types. Type I (immediate) reactions are driven by IgE-mediated mast cell degranulation, releasing histamine and leukotrienes within minutes, as seen in anaphylaxis and allergic asthma. Type II (cytotoxic) reactions involve IgG or IgM binding to cell-surface antigens, activating complement, opsonization, and ADCC to destroy target cells, as in autoimmune hemolytic anemia and Goodpasture syndrome. Some Type II variants produce functional changes via receptor stimulation (Graves disease) or receptor blockade (myasthenia gravis).

Type III (immune complex) reactions occur when antigen–antibody complexes deposit in tissues, activating complement and recruiting neutrophils that cause bystander tissue damage, exemplified by serum sickness, SLE nephritis, and post-streptococcal glomerulonephritis. Type IV (delayed) reactions are uniquely T-cell mediated, involving CD4⁺ Tₕ1-driven macrophage activation (leading to granuloma formation in tuberculosis) and CD8⁺ CTL-mediated cytotoxicity (as in transplant rejection and type 1 diabetes). Key diagnostic tools include the skin prick test and serum tryptase (Type I), direct Coombs test and linear immunofluorescence (Type II), complement levels and granular immunofluorescence (Type III), and the PPD tuberculin test and patch testing (Type IV). Accurate classification is not merely academic—it directly determines therapeutic strategy, from epinephrine and anti-IgE biologics for Type I to plasmapheresis for Type II, complement inhibitors for Type III, and calcineurin inhibitors for Type IV.